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Introduction {#jah31169-sec-0001}
============

In the article Gaziano et al, "Effect of Bromocriptine‐QR (a Quick‐Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects," which published online October 12, 2012, and appeared in the October 2012 issue of the journal (*J Am Heart Assoc*. 2012;1:e002279 doi: [10.1161/JAHA.112.002279](10.1161/JAHA.112.002279)), an error occurred in Table 3. In the row "CV death", column "Bromocriptine‐QR", the originally published numbers of "4 (0.2)" were incorrect. These have been updated to read, "2 (0.1)". The other numbers in the "CV death" row, and columns "Placebo" and "Hazard Ratio" were correct. This typographical error did not affect the analyses, results, or conclusion of the article in any way because the Hazard Ratio number with CI "0.48 (0.07 to 3.43)" for CV death is correct as originally published.

The corrected table is below:

###### 

Impact of Bromocriptine‐QR on CV Death‐Inclusive Composite Cardiovascular End Point and Individual Components of the Composite as Well as on the MACE End Point

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                 Bromocriptine‐QR\                                        Placebo\                                                 Hazard Ratio\
                                                                                 (N=2054), n (%)[a](#jah31169-note-0003){ref-type="fn"}   (N=1016), n (%)[a](#jah31169-note-0003){ref-type="fn"}   (95% CI)
  ------------------------------------------------------------------------------ -------------------------------------------------------- -------------------------------------------------------- ---------------------
  CV death‐inclusive composite cardiovascular end point                          39 (1.9)                                                 33 (3.2)                                                 0.61 (0.38 to 0.97)

  Myocardial infarction                                                          7 (0.3)                                                  9 (0.9)                                                  0.41 (0.15 to 1.11)

  Stroke                                                                         5 (0.2)                                                  6 (0.6)                                                  0.44 (0.13 to 1.43)

  Hospitalization for angina                                                     9 (0.4)                                                  9 (0.9)                                                  0.52 (0.21 to 1.30)

  Hospitalization for heart failure                                              9 (0.4)                                                  6 (0.6)                                                  0.77 (0.27 to 2.16)

  Coronary revascularization                                                     11 (0.5)                                                 8 (0.8)                                                  0.72 (0.29 to 1.80)

  CV death                                                                       2 (0.1)                                                  2 (0.2)                                                  0.48 (0.07 to 3.43)

  Coronary revascularization following a primary end point (ie, CABG after MI)   9 (0.4)                                                  11 (1.1)                                                 0.43 (0.18 to 1.03)

  MACE Composite−myocardial infarction, stroke, CV death                         14 (0.7)                                                 15 (1.5)                                                 0.48 (0.23 to 1.00)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CI, confidence interval; CV, cardiovascular; CABG, coronary artery bypass graft; MACE, major cardiovascular adverse event; MI, myocardial infarction.

Percentage of events per total number per group: 2054 bromocriptine‐QR, 1016 placebo.

The authors regret the error.

The online version of the article has been updated and is available at <http://jaha.ahajournals.org/content/1/5/e002279>.
